Specificity of the HIV-1 Protease on Substrates Representing the Cleavage Site in the Proximal Zinc-Finger of HIV-1 Nucleocapsid Protein.
Amino Acid Sequence
Binding Sites
Drug Design
HIV Infections
/ virology
HIV Protease
/ chemistry
HIV-1
/ physiology
Humans
Models, Molecular
Nucleocapsid Proteins
/ chemistry
Protein Binding
Protein Conformation
Protein Interaction Domains and Motifs
Proteolysis
Recombinant Proteins
Structure-Activity Relationship
Substrate Specificity
Zinc Fingers
HIV-1
human immunodeficiency virus
nucleocapsid protein
protease
retroviruses
specificity
substrate specificity
viral proteases
viral proteins
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
08 06 2021
08 06 2021
Historique:
received:
26
04
2021
revised:
02
06
2021
accepted:
03
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
17
8
2021
Statut:
epublish
Résumé
To explore the sequence context-dependent nature of the human immunodeficiency virus type 1 (HIV-1) protease's specificity and to provide a rationale for viral mutagenesis to study the potential role of the nucleocapsid (NC) processing in HIV-1 replication, synthetic oligopeptide substrates representing the wild-type and modified versions of the proximal cleavage site of HIV-1 NC were assayed as substrates of the HIV-1 protease (PR). The S1' substrate binding site of HIV-1 PR was studied by an in vitro assay using KIVKCF↓NCGK decapeptides having amino acid substitutions of N17 residue of the cleavage site of the first zinc-finger domain, and in silico calculations were also performed to investigate amino acid preferences of S1' site. Second site substitutions have also been designed to produce "revertant" substrates and convert a non-hydrolysable sequence (having glycine in place of N17) to a substrate. The specificity constants obtained for peptides containing non-charged P1' substitutions correlated well with the residue volume, while the correlation with the calculated interaction energies showed the importance of hydrophobicity: interaction energies with polar residues were related to substantially lower specificity constants. Cleavable "revertants" showed one residue shift of cleavage position due to an alternative productive binding mode, and surprisingly, a double cleavage of a substrate was also observed. The results revealed the importance of alternative binding possibilities of substrates into the HIV-1 PR. The introduction of the "revertant" mutations into infectious virus clones may provide further insights into the potential role of NC processing in the early phase of the viral life-cycle.
Identifiants
pubmed: 34201134
pii: v13061092
doi: 10.3390/v13061092
pmc: PMC8227227
pii:
doi:
Substances chimiques
Nucleocapsid Proteins
0
Recombinant Proteins
0
HIV Protease
EC 3.4.23.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Virol. 2005 Apr;79(7):4213-8
pubmed: 15767422
PLoS One. 2020 Jan 9;15(1):e0227062
pubmed: 31917798
J Biol Chem. 1997 Jul 4;272(27):16807-14
pubmed: 9201986
J Biol Chem. 1994 Sep 2;269(35):21948-50
pubmed: 8071314
Biochemistry. 2006 Oct 17;45(41):12617-28
pubmed: 17029416
Biochemistry. 2004 Apr 13;43(14):4304-12
pubmed: 15065874
J Virol. 2005 Jun;79(12):7756-67
pubmed: 15919928
Anal Biochem. 2018 Jan 1;540-541:52-63
pubmed: 29122614
Res Virol. 1992 Sep-Oct;143(5):311-9
pubmed: 1480823
J Virol. 2000 Feb;74(3):1168-77
pubmed: 10627527
Antiviral Res. 1997 Nov;36(2):107-13
pubmed: 9443667
Virology. 2006 Oct 25;354(2):261-70
pubmed: 16904152
FEBS Lett. 1991 Feb 25;279(2):356-60
pubmed: 2001747
Biochemistry. 1993 Apr 6;32(13):3347-53
pubmed: 8384879
J Cell Sci. 1995 Sep;108 ( Pt 9):3039-50
pubmed: 8537443
Antiviral Res. 2001 Feb;49(2):101-14
pubmed: 11248362
J Virol. 1992 Aug;66(8):5087-91
pubmed: 1378515
J Vis Exp. 2019 Jan 16;(143):
pubmed: 30735187
Biochem Biophys Res Commun. 1991 Aug 30;179(1):17-24
pubmed: 1652947
Proteins. 2002 Jul 1;48(1):107-16
pubmed: 12012342
Virus Res. 2008 Jun;134(1-2):39-63
pubmed: 18279991
Virology. 2008 Jun 5;375(2):592-610
pubmed: 18343475
J Gen Virol. 2006 Apr;87(Pt 4):961-965
pubmed: 16528046
J Virol. 1993 Oct;67(10):6159-69
pubmed: 8371356
J Comput Chem. 1986 Apr;7(2):230-252
pubmed: 29160584
Biochemistry. 1992 May 26;31(20):4793-800
pubmed: 1591240
J Virol. 1994 Feb;68(2):757-65
pubmed: 8289379
Arch Biochem Biophys. 1991 Oct;290(1):186-90
pubmed: 1898088
J Virol. 2008 Oct;82(20):10111-7
pubmed: 18701588
Prog Biophys Mol Biol. 1972;24:107-23
pubmed: 4566650
Biochem Biophys Res Commun. 1989 Apr 28;160(2):486-94
pubmed: 2541703
Antimicrob Agents Chemother. 2012 Aug;56(8):4381-90
pubmed: 22664974
Data Brief. 2018 Mar 12;18:203-208
pubmed: 29896511
Curr Pharm Des. 2003;9(22):1803-15
pubmed: 12871198
Eur J Biochem. 2000 Oct;267(20):6287-95
pubmed: 11012683
Curr Top Med Chem. 2003;3(13):1447-57
pubmed: 14529520
J Virol. 1996 Sep;70(9):5840-4
pubmed: 8709202
Protein Eng. 1991 Aug;4(6):695-700
pubmed: 1658777
Biochem Biophys Res Commun. 1990 Jun 29;169(3):1111-6
pubmed: 2114105
Trends Biochem Sci. 1998 Aug;23(8):297-301
pubmed: 9757830